Alerta

Anti-SARS-CoV-2 antibodies and uses thereof

Absstract of: AU2026204287A1

The present disclosure relates to proteins which bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof. un u n

Treatment for Coronavirus infection and associated cytokine toxicity

Absstract of: AU2026204379A1

The present invention relates to novel methods comprising the administration of pentosan polysulfate for treating or preventing coronavirus infection and cytokine- associated toxicity, including cytokine toxicity resulting from aberrant activation of the immune system in coronavirus disease or infection, such as those from SARS-CoV-2. 5 un u n

ANTISENSE OLIGONUCLEOTIDES AS THERAPEUTIC AGENTS AGAINST SARS COV-2

Absstract of: EP4763985A1

The present invention concerns the creation of antisense oligonucleotides (ASOs) with no cytotoxicity that are very active as therapeutic agents in knocking down the replication of SARS-CoV-2 in human cells with pan activity against all known past and current variants.

MERS VACCINE ANTIGEN

Absstract of: WO2026123076A1

The field of the specification relates broadly to Middle East respiratory syndrome coronavirus vaccine (MERS-CoV) antigens and methods of using and manufacturing MERS-CoV antigens. The invention also relates to vaccines, kits, devices and strips comprising the MERS-CoV antigen. The invention also relates to ribonucleic acids encoding a S protein monomer of a coronavirus vaccine (MERS-CoV) antigen and methods of using and manufacturing the ribonucleic acid. The invention also relates to vectors, lipid nanoparticles, RNA vaccines, kits, devices and strips comprising the ribonucleic acid.

ACE2 HOMOLOGOUS PEPTIDE SEQUENCES

Absstract of: US20260167674A1

Peptide sequences that are ACE2 homologues are provided. Compared to the wild-type ACE2 in the host, the peptide sequences bind with higher affinity to the receptor-binding domain (RBD), thus inhibiting this interaction by competitively inhibiting the binding of the virus RBD region of SARS-COV-2 with the human ACE2. The peptide sequences can be included in a pharmaceutical composition.

MONOCLONAL ANTIBODIES SPECIFIC FOR FAS LIGAND AND USES THEREOF

Absstract of: US20260167734A1

Monoclonal antibodies that specifically bind to and block the function of Fas ligand (FasL) are described. The FasL-specific antibodies can be used for the development of therapeutics for the treatment of diseases, disorders and conditions associated with the Fas/FasL signaling pathway, such as cancer, sepsis, ischemia-reperfusion injury, and coronavirus disease 2019 (COVID-19).

( E)-5-ALKOXY-1-PHENYLPENTAN-1-ONE O-(2-( N, N- DISUBSTITUTED AMINO)ETHYL) OXIMES AND THEIR THERAPEUTIC USE FOR COVID-19 DISEASE

Absstract of: WO2026126237A1

The present invention relates to (E)-5-alkoxy-1- phenylpentan-1-one O-(2-(N,N- disubstitutedamino)ethyl) oximes and the methods of preparation thereof. The present invention describes the (E)-5-alkoxy-1-phenylpentan-1-one O-(2-(N,N- disubstitutedamino)ethyl) oximes as potent anti-COVID-19 agent.

PROTACS TARGETING VIRAL ENZYMES FOR PRECISE TREATMENT OF COVID-19

Absstract of: US20260166160A1

Described are proteolysis targeting chimeras (PROTACs) for use in managing and treating infectious disease. Described compositions can be used to inhibit viral replication associated with coronavirus, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes Coronavirus disease 2019 (COVID-19). Methods of synthesizing PROTACs are described. Example PROTAC compositions are provided, including dual targeting compounds having a main protease (Mpro) ligand attached to a linker, an E3 ligase ligand attached to the linker, and a papain-like protease (PLpro) inhibitor attached to the linker. PROTAC compounds useful for degrading Mpro activity and/or PLpro activity, and useful for treating coronavirus infections such as COVID-19, are described.

NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

Absstract of: EP4759827A2

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-CoV-2), comprising a nucleic acid construct encoding a SARS-CoV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in human.

PROTEIN, ADENOVIRUS AND VACCINE AGAINST INFECTION OF SUBTYPE OF SARS-COV-2 OMICRON MUTANT STRAIN XBB

Absstract of: EP4759833A1

The present invention relates to proteins, adenoviruses and vaccines against infection by SARS-CoV-2 Omicron XBB subvariants, which belongs to the medicine field. To address the lack of effective prophylactic and therapeutic drugs for preventing and/or treating infections by SARS-CoV-2 Omicron XBB variants and subvariants thereof, the present invention provides proteins, adenoviruses and vaccines for preventing and/or treating infection by SARS-CoV-2 Omicron XBB subvariants, wherein these vaccines are optimized and designed based on a full-length S protein, and the receptor-binding domain (RBD) and receptor-binding domain and heptad repeat (RBD-HR) sequences in the S protein of the SARS-CoV-2 Omicron XBB subvariants, specifically, XBB.1.16, XBB.1.5, XBB.1.16.6, BA.2.86, EG.5, JN.1, XBB.2.3 and XBB.2, and are capable of aiding the host in combating coronavirus infections, and particularly have a relatively good preventive and therapeutic effect against cross-infections caused by SARS-CoV-2 Omicron XBB subvariants.

A SPATIOTEMPORAL DEEP LEARNING MODEL FOR FORECASTING THE DEVELOPMENT OF SUDDEN EPIDEMICS MODIFIED BY HISTORICAL METEOROLOGICAL DATA

Absstract of: LU604195B1

This invention discloses a spatiotemporal deep learning model for forecasting the development of sudden epidemics, taking into consideration meteorological factors. The method formulates the short-term prediction problem of regional new COVID-19 cases as a predictive technical issue involving multidimensional, gridded spatiotemporal sequences for both input and prediction targets. To address this, a ConvLSTM spatiotemporal deep model is constructed for predicting COVID-19 case numbers. Furthermore, the model is enhanced by considering the modifying effects of meteorological elements, creating a comprehensive spatiotemporal model called the Meteor-ConvLSTM model that integrates historical meteorological factors. This spatiotemporal model produces timely, downscaled, and high-resolution prediction results. This invention is characterized by high predictive accuracy and strong practicality, making it useful for guiding relevant authorities in understanding the epidemic situation and adjusting decision-making strategies.

PEPTIDE WITH NEUTRALIZING ACTIVITY AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2

Absstract of: US20260159544A1

The present invention relates to a peptide that specifically recognizes a protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or a portion thereof, a composition for preventing or treating SARS-CoV-2 infection, comprising the peptide; and a composition for detecting SARS-CoV-2, comprising the peptide.

VIRAL INACTIVATION SPRAY AND GARGLING FORMULATION

Absstract of: US20260157987A1

A viral inactivation composition includes an aqueous solution of citric acid and L-arginine hydrochloride with a pH below 3.5. The citric acid and L-arginine hydrochloride are present in amounts that directly inactivate COVID-19, influenza, and common cold virus in a human upper respiratory system. A method of directly inactivating COVID-19, influenza, and common cold virus in the human upper respiratory system includes administering the viral inactivation composition to a subject. These ingredients are safe, non-toxic, and very effective.

PHARMACEUTICAL COMPOSITION, ITS USE AS A DRUG AND NEW COMPOUNDS, ESPECIALLY FOR TREATING SARS-COV-2 INFECTION

Absstract of: US20260158015A1

The present invention relates to a compound comprising a compound having formula (I) below:wherein R1, R2 and R3 are as defined, or a pharmaceutically acceptable salt thereof, for use in the prevention or in the treatment of an infection.The invention also relates to a pharmaceutical composition comprising the compound, for use in the prevention or in the treatment of an infection.

MULTICISTRON EXPRESSION VECTOR FOR COVID-19 VACCINE

Absstract of: US20260159553A1

The present invention provides an expression vector comprises gene of interest encode more than one structural protein to enhance immune responses against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants. Furthermore, the expression vector to produce mRNA expresses more than one structural protein to generate immune response against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) and its variants.

COMPOSITIONS SUITABLE FOR USE IN A METHOD FOR ELICITING CROSS-PROTECTIVE IMMUNITY AGAINST CORONAVIRUSES

Absstract of: US20260158134A1

Immunogenic compositions and methods of use thereof, for eliciting an immune response against multiple coronaviruses, using a single vaccine composition are described. The compositions include an antigen from more than one pathogen, for example, more than one member of the β-coronavirus family, for example, SARS-CoV and MERS-CoV. Exemplary antigens include the receptor binding domain (RBD) of the coronavirus spike protein or a fragment thereof. The disclosed compositions are administered to a subject in need therefore, to generate an immune response against more than one pathogen, represented by the source of the antigens in the construct.

VARIANT STRAIN-BASED CORONAVIRUS VACCINES AND USES THEREOF

Absstract of: US20260158135A1

0000 The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.

At-Home Covid Nucleic Acid Detection Kit For Rapid Molecular Diagnostics

Absstract of: US20260158492A1

The present invention describes kits and methods for rapid detection of nucleic acid sequences in real-time and in any setting. Unique features of this kit include isothermal nucleic acid extraction in Unit 1, and amplification, labeling, and signal detection in Unit 2 (FIG. 1). These units can be operated separately with manual transfer of product from one to the other or can be put together in a fashion where user places sample into inlet of Unit 1 and observes results in detection chamber of Unit 2. Several versions of this kit can be developed using different sequence-specific primers and probes to detect any nucleic acid sequence (DNA or RNA) in a multiplex fashion. In a preferred embodiment, visual detection of amplified signal is done using Lateral Flow Strips, eliminating the need for any additional complex equipment. Such a kit can be easily developed and manufactured to assist in the mitigation response to any pandemic, especially for COVID-19. The COVID-19 kit is called an At-Home COVID test (AH-COV).

COMPOSITION FOR THE TREATMENT OF COVID-19

Absstract of: US20260158044A1

0000 A composition for the treatment of COVID-19 is disclosed, including a first composition including approximately 10 mg of dexamethasone. The first composition is combined with a second composition including between approximately 48 mg to approximately 80 mg of triamcinolone acetonide, sodium chloride, benzyl alcohol, carboxymethylcellulose sodium, and polysorbate 80.

SYNTHESIS OF (1R,2S,5S)-N-(1S)-1-CYANO-2-(2-OXOINDOLIN-3-YL)ETHYL-3-(2S)-3,3-DIMETHYL-2-(2,2,2-TRIFLUOROACETYL)AMINOBUTANOYL-6,6-DIMETHYL-3-AZABICYCLO3.1.0HEXANE-2-CARBOXAMIDE

Absstract of: WO2026122604A1

The present invention is directed to method of synthesis of (1R,2S,5S)-N-(1S)-1-cyano-2- (2-oxoindolin-3-yl)ethyl-3-(2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetyl)aminobutanoyl-6,6- dimethyl-3-azabicyclo3.1.0hexane-2-carboxamide, which are useful in the treatment of coronavirus infection including COVID-19 resulting from SARS-CoV-2 infection.

METHOD FOR TREATMENT OF CORONAVIRUS INFECTION

Absstract of: US20260158055A1

The present invention involves a novel method for treatment of coronavirus infection, including SARS-COV-2. The method comprises administering stannous protoporphyrin and/or cyanocobalamin to a human patient at risk for developing complications from coronavirus infection. The method is particularly useful where a patient has been diagnosed with coronavirus infection or has been exposed to coronavirus but has not developed symptoms of coronavirus infection.

METHODS OF ASSIGNING A COVID PATHOLOGICAL TYPE AND COMPOSITIONS FOR PRACTICING THE SAME, AND METHODS OF TREATING A SUBJECT FOR CHRONIC COVID-19

Absstract of: WO2025029797A1

Methods of assigning a COVID pathological type for a subject suffering from COVID-19 are provided. Aspects of the methods include assigning a COVID pathological type for the subject based on a determined quantitative, multiplex cytokine/chemokine panel in a test sample from the subject. Also provided are methods of treating a subject (e.g., a long hauler subject) for chronic COVID-19. Aspects of such methods include administering to the long hauler subject a CCR5/CCL5 interaction inhibitor to treat the long hauler subject. Also provided are compositions for use in practicing the methods. The methods and compositions find use in a variety of applications, including patient stratification, treatment and therapy determination and therapy response assessment.

COVID-19 Treatment of COVID-19 and Methods Therefor

Absstract of: JP2025032179A

To provide a vaccine composition to induce immunity against a coronavirus in a subject.SOLUTION: A vaccine composition comprises a recombinant nucleic acid that encodes N-ETSD, a modified nucleocapsid protein that includes an endosomal targeting sequence, and/or that encodes S-Fusion, a modified spike protein that has improved surface expression. The vaccine may be formulated as a recombinant nucleic acid, recombinant yeast, and/or recombinant virus such as an adenovirus and can be administered via injection and/or mucosal delivery.SELECTED DRAWING: Figure 25

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Absstract of: US20260151476A1

0000 Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-COV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

COMPOSITIONS AND METHODS FOR TREATING BIOFILMS AND NEUTROPHIL EXTRACELLULAR TRAP FORMATION

Absstract of: US20260152531A1

0000 Provided herein is a synthetic polypeptide derived from High Mobility Group Box 1 (HMGB 1) host protein that can both disrupt bacterial biofilms and prevent Neutrophil Extracellular Trap (NET) formation. Also provided herein are methods to disrupt aberrant or excessive NET formation that are particularly well-suited to treat high-risk populations such as those infected with SARS CoV-2, sepsis, autoimmune diseases e.g., systemic lupus erythematosus, rheumatoid arthritis, Type I diabetes mellitus, small vessel vasculitis, autoinflammatory diseases e.g., gout, inflammatory bowel disease, and metabolic diseases e.g., Type 2 diabetes and obesity.

COMPOSITIONS AND THERAPEUTIC METHODS FOR TREATING CHRONIC SEQUALAE FOLLOWING VIRAL INFECTIONS

Absstract of: US20260151414A1

0000 Embodiments of therapeutic protocols to treat Post-Acute Sequelae SARS-COV-2 infection (“PASC”), a.k.a. “long Covid,” are described. The PASC treatment protocols focus on a moderating a hyperimmune response; destroying and removing the SARS COV-2 spike protein from the gut and body, detoxifying the body and the brain; replenishing key nutrients; mitigating depression and anxiety; and a regimen of physical and mental exercises. A standard six-week protocol and a shorter, three-week protocol are disclosed for those with a milder form of PASC are disclosed.

ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS AND METHODS

Absstract of: US20260151415A1

0000 Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

A SARS-COV-2 NUCLEOCAPSID PROTEIN-SPECIFIC VNAR ISOLATED FROM A NAÏVE PHAGE LIBRARY

Absstract of: WO2026112937A1

Relate to an isolated vNAR single domain antibody that specifically binds to SARS-CoV-2 nucleocapsid protein, and a process for preparing the same.This isolated vNAR single domain antibody are also included.

IMPROVED METHODS OF PRODUCING A LIPIDATED PROTEIN

Absstract of: EP4751733A2

The present invention relates to method of producing a lipidated protein, a pharmaceutical composition comprising the protein of any of SEQ ID NOs: 1, 2, and/or 3 and/or the lipidated form of a protein comprising the protein of SEQ ID NO: 7 (C-TAB.GS) and/or SEQ ID NO: 8 (C-TAB.G5.1), especially the protein of SEQ ID NO: 12 (Lip-C-TAB.G5.1), and/or a lipidated form of a protein comprising the protein of SEQ ID NO: 15 (Spike protein of SARS-CoV-2) and/or a lipidated form of a protein comprising the any of the proteins of SEQ ID NOs: 16-22 (hMPV F protein), and the pharmaceutical composition for use as a medicament, particularly a vaccine and/or for use in a method for eliciting an immune response in a human against Lyme disease, a disease caused by Clostridium difficile or hMPV and/or of SARS-CoV-2 (COVID-19).

SYSTEM FOR DIAGNOSIS OF RESPIRATORY DISEASES USING ANALYSIS OF EXHALED BREATH AND AEROSOLS

Absstract of: EP4751641A2

Disclosed are methods and devices for analyzing non-volatile organics in exhaled breath and other aerosols using various diagnostic tools that enable rapid, low cost point of care assays for several diseases including respiratory tract diseases such as COVID-19. The disclosed methods and systems selectively capture non-volatile organics in exhaled breath and other aerosols in a packed bed column. The non-volatile organics are eluted and samples are analysis using diagnostic devices including MALDI-TOFMS. The disclosed systems and methods provide for a diagnostic test result in less than about 20 minutes and provides for autonomous operation with minimal human intervention.

ANTIBODIES AGAINST COVID-19 AND OTHER HUMAN CORONAVIRUSES

Absstract of: WO2025022303A1

The present invention relates to monoclonal antibodies or antigen-binding portion thereof that have a potent neutralizing activity against Coronavirus, in particular against at least one virus selected from SARS-CoV-2, SARS-CoV-1 and variants thereof. The invention relates also to the use of such monoclonal antibodies or antigen-binding portion thereof in therapy, prophylaxis, and diagnosis of Coronavirus, in particular SARS-CoV-2 and/or SARS-CoV-1 dependent diseases.

19 Study on Correction Methods for Impact Data in Model Training: Focusing on the Shock to Jeju Island Tourism Demand Due to COVID-19

Absstract of: KR20260080874A

본 발명은 코로나19에 따른 제주 입도수요 충격 데이터 보정 방안을 기반으로한 모델 학습을 위한 충격 데이터 보정 방안 연구 에 관한 것으로서 제주 관광 수요 예측 정확도를 높이고 외부 충격에 대한 대응 능력을 강화하는 데 기여한다. 또한 체계적 표준화가 미흡한 현 관광 산업의 데이터 분석 환경에 새로운 방법론을 제시함으로써, 데이터 기반의 과학적 분석과 의사 결정이 가능한 체계를 구축하는 데 기여할 것으로 기대된다.하도록 함으로써 기존의 제주도 관광 산업은 지역 GRDP의 21%를 차지하며 2023년 관광객 1,400만 명을 기록했다. 그러나 관광 수요예측은 계절, 경제, 사회적 요인의 영향 및 복잡한 비선형 관계를 가지고 있어 선형 중심의 전통적 통계모형으로는 외생 요인들의 영향을 효과적으로 반영하기 어렵다. 특히 코로나19와 같은 충격 데이터를 단순 제거하면 중요한 정보가 손실될 수 있다. 따라서 본 연구는 통계모형과 기계학습을 결합해 충격 데이터의 특성을 반영한 새로운 관광 수요 예측 방법을 제시한다. 문제점을 해소 하도록 한 것이다.즉 본 발명은, 기존 관광 산업의 수요예측은 기본적 통계모델(Arima)로만 진행됨 에 있어서 통계모형과 기계학습을 결합해 충격 데이터의 특성을 반영한 새로운 관광 수�

Non-passive anti-viral and nanofilter based respirators

Absstract of: US12643063B1

0000 The present development is a nanofilter, i.e. a filter material that comprises inorganic nanowires impregnated into a non-woven polymer or cloth fabric material. The nanofilter comprises a fabric infiltrated with a nanowire powder slurry selected from anatase titania (TiO<2>), zinc oxide (ZnO), silica, tin oxide, alumina (Al<2>O<3>), or combinations thereof. Exemplary fabrics include a non-woven polymer and a cotton fabric cloth. The nanowire powder slurry effectively produces a coating on the fabric. Optionally, the nanowires may be functionalized using nanoparticles and/or disinfecting salt particles. The infiltrated nanowires form a porous network with sub-micron scale openings and provide filtration of any airborne particles, liquid droplets and viruses including COVID 19. The nanofilter may be used in a variety of applications, such as a nanofilter respirator as described herein.

CORONAVIRUS VACCINE

Absstract of: MX2026005926A

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

WS-635 FOR USE IN THE TREATMENT OR PREVENTION OF SARS-COV-2 INFECTION

Absstract of: CA3126560A1

A method of treating or preventing a Coronaviridae infection in a subject comprising administrating a therapeutically effective amount of a compound of Formula I or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the Coronaviridae comprises at least one selected from 2019-nCov virus, HCov 229E virus, SARS virus, MERS virus,

SARS-CoV-2 SARS-CoV-2 Antiviral composition for SARS-CoV-2 or SARS-CoV-2 variants comprising osimertinib as an active ingredient

Absstract of: KR20260078113A

본 발명은 오시머티닙(osimertinib)을 유효성분으로 포함하는 SARS-CoV-2 바이러스 또는 SARS-CoV-2 변이체 바이러스에 대한 항바이러스용 조성물에 관한 것으로서, 세포 생존율 감소와 무관하게 hACE2를 발현하는 세포 및 3D 스페로이드에 처리 시 야생형뿐만 아니라 변이체 바이러스의 감염이 감소되는 효과를 가지므로, ARS-CoV 바이러스 또는 SARS-CoV-2 변이체 바이러스의 감염 예방, 개선 및 치료에 사용할 수 있을 것으로 기대된다.

COMPOSITIONS IMMUNOGENIC AGAINST RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF USE THEREOF

Absstract of: WO2026108766A1

Provided herein are live attenuated viruses for protection against respiratory syncytial virus (RSV) and/or coronavirus Sars-CoV-2. The live attenuated chimeric virus strains utilize a master backbone based on a live attenuated influenza virus (LAIV), which includes a deletion of the viral virulence element, the NS1 (non-structural protein 1) (DeLNS1). These chimeric strains are engineered to express one or more antigens of RSV alone or in combination with Sars-CoV-2. The chimeric virus strain can protect a subject in need thereof against a challenge from any of RSV, Sars-CoV-2, influenza, or a combination thereof. This viral vector system offers an important strategy for developing highly attenuated and immunogenic live attenuated vaccines with the capacity to induce protective immunity against the three respiratory infections.

COMBINATION VACCINES AGAINST CORONAVIRUS INFECTION, INFLUENZA INFECTION, AND/OR RSV INFECTION

Absstract of: US20260144861A1

0000 This disclosure relates to the field of RNA to prevent or treat multiple infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection, and/or RSV infection and inducing effective coronavirus, influenza virus, and/or RSV antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject (i) a bivalent RNA vaccine encoding peptides or proteins comprising epitopes of SARS-CoV-2 spike proteins (S proteins) and (ii) a tetravalent RNA vaccine encoding peptides or proteins comprising epitopes of hemagglutinin (HA), for inducing an immune response against coronavirus S proteins, in particular S proteins of SARS-CoV-2, and influenza proteins, in particular HA proteins of type A and type B influenza viruses, in the subject.

VHH AGAINST SARS-COV2 AND FUSION PROTEIN

Absstract of: WO2026110758A1

Problem To provide a VHH which specifically binds to receptor binding domains of spike proteins of various types of variants of SARS-CoV2. Solution A VHH having any one or more of the characteristic properties mentioned below can recognize various types of variants of SARS-CoV2. (a) The VHH binds to Wuhan-Hu-1, delta variant, or micron variant of SARS-CoV2. (b) CDR1, CDR2, and CDR3 include the amino acid sequences represented by SEQ ID NOs: 1, 2, and 3, respectively; and/or (c) the VHH recognizes the amino acid sequence represented by SEQ ID NO: 4 and/or the amino acid sequence represented by SEQ ID NO: 5. This fusion protein which is obtained by fusing the VHH with ACE2 or an Fc form thereof enhances the SARS-CoV2 neutralizing capability and can be used in a pharmaceutical composition for treating or preventing COVID-19.

ENGINEERED SARS-COV-2 ANTIBODIES WITH INCREASED NEUTRALIZATION BREADTH

Absstract of: US20260146077A1

0000 Disclosed are monoclonal antibodies, antigen binding fragments, and bi-specific antibodies that specifically bind SARS-CoV-2. Also disclosed is the use of these antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies. In some embodiments, the SARS-CoV-2 is the BA.4 or BA.5 variant.

COMPOUNDS AND METHODS FOR TREATING DISEASES CAUSED BY VIRUSES AND BACTERIA

Absstract of: US20260146062A1

0000 Compositions and methods are provided for inhibiting the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

COMPOUNDS SUITABLE FOR CARDIOVASCULAR DISEASE TREATMENT

Absstract of: WO2026112441A1

The present disclosure relates to compositions and methods, including prodrugs of (S)-3-(3-(((3,4- dimethoxybicyclo4.2.0octa-1,3,5-trien-7-yl)methyl)(methyl)amino)propyl)-7,8-dimethoxy-1,3,4,5-tetrahydro-2H- benzodazepin-2-one that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, sinus tach (e.g. inappropriate sinus tachycardia (IST)), postural orthostatic tachycardia syndrome (POTS), coronavirus (COVID-19) (e.g. long COVID) and COVID-associated cardiovascular abnormalities, supraventricular tachycardia (SVT), tachycardia (e.g. rapid heart rate, atrial tachycardia), heart failure (e.g. congestive heart failure (CHF), systolic heart failure, pediatric heart failure, chronic heart failure), myocardial ischaemia, angina (e.g. angina pectoris), myocardial infarct, rhythm disturbances (e.g. supraventricular rhythm disturbances), chest pain, cardiomyopathy, coronary artery disease, and left ventricular dysfunction (LVD).

VALACYCLOVIR AND CELECOXIB IN COMBINATION WITH NIRMATRELVIR AND RITONAVIR FOR THE TREATMENT OF COVID-19

Absstract of: AU2024395949A1

The present disclosure relates to methods of diseases and/or conditions associated with Covid-19 infection, including long COVID, comprising administration of a COX-2 inhibitor, an antiviral compound, and one or more additional active ingredients, such as a combination of nirmatrelvir and ritonavir, molnupiravir, BCG vaccine, or ivermectin.

COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV2 INFECTION

Absstract of: ZA202301746B

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Therapeutic method against viral infection

Absstract of: US12636282B1

Coronavirus disease of 2019 (COVID-19) is an acute viral infection that can trigger complicated immune system responses depending on the host. This disclosure discloses immunotherapy methods combining immunomodulators and antivirals to prevent and to reduce the severity of a COVID-19 infection. Successful treatment of COVID-19 requires prevention, early recognition and detection, the ruling out of co-infections, serial laboratory monitoring, and clinical monitoring for worsening and timely treatments during the acute phase and post-viral syndrome. Using this disclosure as preventive, management and therapeutic options for COVID-19, infected patients can be more resilient to viral challenges, recovering faster with less organ damages and adverse residual effects.

ANTICORPS CONTRE LE SARS-COV-2 ET LEURS PROCÉDÉS D'UTILISATION

Absstract of: MA70469B1

La présente invention concerne des anticorps et des fragments de liaison à l'antigène de ceux-ci qui se lient spécifiquement à la protéine de spicule du SARS-CoV-2 et des procédés de fabrication et d'utilisation de ceux-ci. Les anticorps peuvent être utilisés, par exemple, dans la prophylaxie, la prophylaxie post-exposition, ou le traitement d'une infection par le SARS-CoV-2. Les anticorps peuvent également être utilisés pour détecter le SARS-CoV-2, notamment une infection chez un sujet.

VARIANT STRAIN-BASED CORONAVIRUS VACCINES

Absstract of: US20260137772A1

The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-COV-2, as well as methods of using the vaccines.

AIR FILTER WITH PATHOGEN MONITORING AND INACTIVATION

Absstract of: US20260137077A1

An improved technology for inactivation of viruses, for example the SARS-COV-2 virus that is causing the Covid-19 pandemic, is described. The technology can include a device that includes a substrate coated in a polymer that is infused with a pathogen inactivating material. In various embodiments, at a given time, a portion of the pathogen inactivating material is exposed to the environment, and the device is configured to periodically or intermittently expose additional pathogen inactivating material to the environment. For example, the polymer can be ablative or sacrificial.

PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS

Absstract of: US20260139860A1

In alternative embodiments, provided are products of manufacture, including automobiles and buildings, and multiplexed systems such as ventilation systems, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a microbial infection, such as bacterial and viral infections, including the common respiratory viruses such as influenza virus, respiratory syncytial virus, parainfluenza virus, adenovirus, rhinovirus, human metapneumovirus, hantaviruses, enterovirus, coronavirus (such as a SARS, MERS or COVID-19 infection), or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales.

Aptamers specifically binding to human coronavirus and use thereof

Absstract of: KR20260072673A

본 발명은 인간 코로나바이러스에 특이적으로 결합하는 압타머와 이의 용도에 관한 것으로, 본 발명에서 발굴한 코로나바이러스에 특이적으로 결합하는 신규한 압타머들은 종래의 항체에 비해 온도 및 pH에 안정적이며, 투여가 용이하고, 변형이 용이한 장점이 있으며, 피코몰(pM) 수준의 높은 결합 친화도로 SARS-CoV-2 spike 단백질의 subunit 2에 고특이적으로 결합하고, 코로나바이러스와 숙주 세포 사이의 막 융합을 억제함으로써 바이러스의 숙주 세포로의 유입을 억제하는 효가가 있으므로, 코로나바이러스의 검출, 감염 진단, 감염증의 예방 및 치료 용도로 활용할 수 있다.

BIOMARKER FOR DIAGNOSING ASTHMA CAUSED BY SARS-COV-2 INFECTION AND USES THEREOF

Absstract of: WO2026106262A1

The present invention relates to a biomarker composition for diagnosing asthma caused by SARS-CoV-2 infection, and uses thereof. Through a change in the expression of CDHR3, SCGB3A2, PLAU, or NPY, which are biomarkers according to an embodiment of the present invention, it was confirmed that patients infected with SARS-CoV-2 have a higher incidence of asthma compared with healthy individuals, and thus the biomarker can be widely applied in the fields of diagnosis of SARS-CoV-2-induced asthma and drug screening.

METHODS OF TREATING LUNG CANCER AND OTHER CANCERS BY RECOMBINANT SARS-COV-2 SPIKE S1

Absstract of: US20260139008A1

Described herein is a novel method of treating cancer in a patient in need thereof, comprising administering a therapeutically effective amount of SARS-CoV-2 Spike 51 polypeptide.

Colorimetric and Multiplexed Isothermal RNA- and Antibody-Based Assay for SARS-CoV-2 and Other Viral Diagnostics and Cell Analysis

Absstract of: US20260139332A1

0000 Methods, devices, and kits for performing rapid, highly sensitive, high throughput, accurate, and flexible detection and quantification of antigens based on highly optimized rolling circle amplification are provided. The methods, devices, and kits can be used to detect and track an emergent virus or other pathogen, including SARS-COV-2, to test and diagnose individual patients with respect to a specific pathogen or disease, including COVID-19, and to detect and analyze cellular nucleic acids. The methods and devices also can be used to detect fragments and variants of DNA or RNA, including those present in cancer cells. The methods, devices, and kits are suitable for use in both high throughput screening carried out in centralized testing laboratories and in point-of-care testing devices used in the field, at home, in the workplace, or at public facilities for rapid detection and diagnosis.

SYSTEM FOR CARGO TRANSPORT

Absstract of: US20260138838A1

A system for cargo transport in the field of intermodal logistics aims to solve supply chain-related disruptions experienced during the Covid-19 pandemic. Cargo frame cargo ships (24), cargo frame barges (26), cargo frame docks (20), 3-axis structures, and 3-axis hoists (10) utilize a cargo frame to bundle series 1 freight containers, vehicles, dry-bulk, wet-bulk, and other general cargoes in a stackable, modular manner. Purpose-built 3-axis structures increase the footprint of ports where cargo frames are stacked, stored, and retrieved. Semi-truck queueing towers (22), and freight car transshipment yards (34) allow for timely coordination of cargo transfer at a multi-level port (48), increasing the throughput of intermodal cargoes.

HUMAN ANTIBODY AGAINST CORONAVIRUS VARIANTS OR ANTIGEN-BINDING FRAGMENT THEREOF

Absstract of: US20260139035A1

It is an object of the present invention to provide an antibody against coronavirus (SARS-CoV-2) variants. It is also an object of the present invention to provide a pharmaceutical composition against coronavirus infection using the antibody. The present invention provides an antibody or antigen-binding fragment thereof that binds to the spike protein of the coronavirus and has the ability to neutralize coronaviruses, including the Omicron variant, and a pharmaceutical composition for the prevention or treatment of coronavirus infection, which contains the antibody or an antigen-binding fragment thereof.

THERAPEUTIC AGENT FOR CORONAVIRUS INFECTION

Absstract of: US20260139062A1

The present invention provides a pharmaceutical composition for use in therapy or prevention of the novel coronavirus (SARS-CoV-2) disease 2019 (COVID-19), the composition containing an IL-10 inhibitor.

EVOLUTION OF FLUOROGENIC SENSORS

Absstract of: US20260139001A1

Described herein is evolution strategy that leverages highly efficient tRNA charging chemistry for cell-free ribosomal translation of proteins, including fluorogenic sensors. The fluorogenic sensors provided are capable of detecting targets, including antigens such as SARS-CoV-2 variants (e.g., Omicron variants).

PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2

Absstract of: US20260137677A1

0000 Compounds of formula (I) are disclosed: or a salt, solvate or tautomer thereof, wherein; Mcomprises a SARS-CoV-<2 >main protease ligand, X comprises a divalent exit vector; Xi comprises a divalent exit vector; a and b are independently selected from 1 or 2; L comprises a divalent linker, and Ucomprises an E3 ubiquitin ligase ligand. Also disclosed are pharmaceutical compositions comprising such compounds or combinations, and methods and reagents using the compounds. Compounds may have therapeutic uses and uses in research.

SYSTEM FOR EVALUATING PERSON SUFFERING FROM COVID-19, METHOD FOR EVALUATING PERSON SUFFERING FROM COVID-19, AND COMPUTER PROGRAM

Absstract of: WO2026100590A1

Problem To suggest the possibility of olfactory/gustatory abnormality (impairment) by means of a numerical value based on the metabolism of tryptophan in the kynurenine pathway. Solution A system 1 for evaluating a person suffering from COVID-19 comprises: an acquisition means 10 for acquiring a numerical value based on the metabolism of tryptophan in the kynurenine pathway obtained by analyzing serum S during an acute phase of COVID-19 in a person suffering from COVID-19; and an evaluation means 30 that indicates the possibility of olfactory/gustatory abnormality (impairment) in the person suffering from COVID-19 on the basis of the numerical value (for example, a KTR value or a blood concentration value for quinolinic acid).

WTACID PEPTIDES FOR PANCREATIC CANCER AND LUNG CANCER

Absstract of: WO2026102096A1

In one aspect, the invention relates to peptides comprising a) a cell penetrating peptide (CPP) and b) a fragment of the SARS-CoV-2 spike SI peptide, derivatives thereof, and related peptides, which are useful as therapeutic agents for treating cancer; pharmaceutical compositions comprising the peptides, and methods of treating, reducing or preventing cancer, methods of increasing LDH release in a cancer cell, methods of decreasing MT I metabolism m a cancer cell, and methods of inducing apoptosis in a cancer cell using the disclosed peptides and compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS

Absstract of: US20260130987A1

The invention relates to vaccination of human subjects, in particular elderly, against pneumoccocal and COVID-19 infections.

TREATMENT OF VIRAL INFECTIONS WITH COMBINATION OF PIKFYVE KINASE INHIBITORS AND TMPRSS-2 INHIBITORS

Absstract of: US20260130921A1

The present invention relates to methods of treating viral infections including COVID-19 and compositions with a combination of (i) an inhibitor of phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) and (ii) an inhibitor of transmembrane serine proteinase 2 (TMPRSS-2).

BROADLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 AND SARS-COV VARIANTS

Absstract of: AU2024408954A1

Disclosed are monoclonal antibodies, antigen binding fragments, and multi-specific antibodies that specifically bind a coronavirus spike protein, such as SARS-CoV-2. Also disclosed is the use of these antibodies and multi-specific antibodies for inhibiting a coronavirus infection, such as a SARS-CoV-2 infection. In addition, disclosed are methods for detecting a coronavirus, such as SARS-CoV-2, in a biological sample, using the disclosed antibodies and multi-specific antibodies.

TREATING LONG COVID-19 WITH UROLITHINS

Absstract of: WO2023031673A1

The invention provides methods useful for treating post-viral illness, including long COVID-19, in a subject afflicted therewith comprising administering to the subject an urolithin.

SARS-CoV-2 universal recombinant antigen polypeptides, polynucleotides and uses thereof

Absstract of: US20260130988A1

0000 Proposed herein are a polypeptide including a SARS-CoV-2 universal antigen amino acid sequences, and a polynucleotide encoding the polypeptide. Also proposed herein are a vaccine composition for preventing SARS-CoV-2 infection, and a pharmaceutical composition for preventing or treating SARS-CoV-2 infection, wherein the vaccine and pharmaceutical compositions contain the polypeptide or polynucleotide as an active ingredient. The present invention provides a universal antigen polypeptide capable of responding not only to wild-type SARS-CoV-2 and currently circulating SARS-CoV-2 variants, but also to hypothetical SARS-CoV-2 variants, as well as a polynucleotide encoding the same. In addition, the present invention provides a SARS-CoV-2 universal antigen polypeptide with enhanced structural stability through amino acid substitutions at specific positions of the universal antigen polypeptide, and a polynucleotide encoding the same. Furthermore, the present invention provides a vaccine composition and a pharmaceutical composition comprising the SARS-CoV-2 universal antigen polypeptide or the polynucleotide as an active ingredient.

Anti-Viral Therapeutic Peptides, Conjugates, and Methods of Use Thereof

Absstract of: US20260131011A1

The application provides a plurality of new therapeutic peptides, which are designed based on the heptad repeat region of a viral spike fusion protein (such as SARS-Cov2, MERS-CoV, or HCov-OC43) or a heptad repeat region in a paramyxovirus (such as Measles, Nipah, or HPIV3)), new therapeutic conjugates that comprising these therapeutic peptides, and methods of using the therapeutic peptide conjugates for the treatment of a condition or disease associated with a viral infection.

SARS-CoV-2 OMICRON BINDING PROTEINS AND METHODS OF USE THEREOF

Absstract of: US20260132187A1

Certain embodiments of the invention provide isolated anti-Omicron sdAbs, as well polypeptides and protein molecules comprising such sdAbs. Certain embodiments of the invention also provide methods of using these sdAbs, and protein molecules (e.g., monospecific or bispecific binder) for treating or preventing a SARS-CoV-2 Omicron infection.

TGF-SS INHIBITION AND ENGINEERED T-CELLS FOR THE TREATMENT OF COVID-19 SEQUELAE AND VIRUS-INDUCED HYPERINFLAMMATION

Absstract of: WO2025012121A1

The invention relates in one aspect to a TGF-β inhibitor for use in the treatment of virus-induced hyperinflammation or (post-)COVID-19 infection symptoms or sequelae, wherein the patient is suffering from or experiencing elevated (above-normal) expression, excretion and/or blood levels of transforming growth factor-β (TGF-β) and/or interferon. The invention relates also to a TGF-β inhibitor for use in the treatment of COVID-19-induced hyperinflammation or (post-)COVID-19 symptoms or sequelae or Long-COVID-19. In another aspect the invention relates to a method for stimulating T cells and to a T-cell for the use in the treatment of virus reactivation and/or SARS- CoV-2-induced hyperinflammation.

COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19

Absstract of: AU2024367811A1

The present disclosure provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

IMMUNOGENIC COMPOSITIONS AGAINST THE OMICRON VARIANT OF SEVERE ACUTE RESPITORY SYNDROME CORONAVIRUS 2 (SARS-COV-2)

Absstract of: US20260124294A1

The present invention relates to immunogenic compositions against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), especially to immunogenic compositions having recombinant SARS-CoV-2 S proteins derived from Omicron subvariants.

TREATMENT USING A ONE-TO-STOP ATTENUATED SARS-COV-2 VIRUS

Absstract of: US20260124293A1

0000 The invention relates to pharmaceutical product comprising a polynucleotide for use in the prevention or treatment of a SARS-CoV-2 virus infection wherein said SARS-CoV-2 virus is not a Wuhan wild-type SARS-CoV-2 virus. The polynucleotide encodes an attenuated human coronavirus or a fragment thereof, wherein the polynucleotide comprises at least 20 one-to-stop codons, wherein a one-to-stop codon is i) a different but synonymous codon compared to the corresponding codon in a natural human coronavirus genome and ii) differs by one nucleotide from a STOP codon.

SALT FORM OF PEPTIDE HAVING ANTIVIRAL ACTIVITY

Absstract of: WO2026094984A1

Provided, as an anti-SARS-CoV-2 peptide drug, is an optimal salt form of a peptide that binds to a receptor-binding domain (RBD) in SARS-CoV-2.　A sodium or potassium salt of a peptide according to the present invention has, in a direction from an N-terminus to a C-terminus, a first region including a first helix and a second region including a second helix. The first region and the second region each include a site that binds to a receptor-binding domain (RBD) in SARS-CoV-2. A bond is formed between amino acid residues within five residues on the N-terminus side in the sequence of the site that binds to the receptor-binding domain (RBD) in SARS-CoV-2 in the first region and amino acid residues within five residues on the C-terminus side in the sequence of the site that binds to the receptor-binding domain (RBD) in SARS-CoV-2 in the second region, and the peptide binds to the receptor-binding domains (RBD) in SARS-CoV-2.

Substituted Pyrazolo3,4-bpyridine Compounds and Methods of Use Thereof

Absstract of: US20260125399A1

present disclosure relates, in part, to SARS-CoV-2 papain-like protease (PLpro) inhibitors of Formula (I), pharmaceutical compositions thereof, and methods of using the same for promoting an antiviral effect in a subject and/or treating, preventing, and/or ameliorating a viral infection in a subject:

METHODS FOR MONITORING IMMUNE STATUS OF A POPULATION

Absstract of: US20260126442A1

The present invention relates to methods for monitoring the immune status of a population by detecting and/or quantifying antibodies present in wastewater. The invention further provides methods and kits for monitoring the presence of an antibody to SARS-CoV-2 or a variant thereof within a population by detecting and/or quantifying SARS-CoV-2-specific antibodies in wastewater.

USE OF LIPID NANOPARTICLES AND IMMUNE CHECKPOINT INHIBITORS IN THE TREATMENT OF CANCER

Absstract of: US20260124295A1

Disclosed are methods of increasing sensitivity of a tumor to treatment with an immune checkpoint inhibitor (ICI). The methods comprise administering to a subject in need thereof a composition comprising a lipid nanoparticle comprising mRNA encoding SARS-CoV-2 Spike protein, and administering an ICI to the subject, where the composition comprising a lipid nanoparticle comprising mRNA encoding SARS-CoV-2 Spike protein is optionally administered within 100 days of administration of the ICI, including with 30 days of administration of the ICI. In some aspects, the methods comprising administering to a subject in need thereof a composition comprising a lipid nanoparticle comprising mRNA encoding non-tumor antigens, and administering an ICI to the subject where the composition comprising a lipid nanoparticle comprising mRNA encoding non-tumor antigens is optionally administered within 100 days of administration of the ICI, including with 30 days of administration of the ICI.

COMPOSITIONS OF IL-6/IL-6R ANTIBODIES AND METHODS OF USE THEREOF

Absstract of: US20260125483A1

The present disclosure provides compositions and methods for the treatment of coronavirus infections, such as SAR-CoV, SARS-CoV-2, and MERS-CoV. The compositions include antibodies targeting the IL-6 receptor complex, antibodies targeting CD3, dactinomycin, and combinations thereof. The methods of treatment include administration of antibodies and combination therapies to reduce or eliminate symptoms associated with coronavirus infection or pulmonary inflammatory disease.

HYALURONIC ACID DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: EP4737486A1

0001 The present invention relates to a hyaluronic acid derivative as shown in formula I, and a preparation method thereof and the use thereof in the preparation of an anti-infection drug. The structure of the compound or the pharmaceutically acceptable salt thereof of the present invention is significantly different from that of commercially available hyaluronic acid substances such as TCIsHA and R&D HA, and the compound or the pharmaceutically acceptable salt thereof can form a molecular structure recognized by HepSS-1. The molecule with the new structure can achieve an anti-infection effect by means of inhibiting the binding of SARS-Cov-2 spike protein to ACE2 of a host cell, and is less likely to cause serious adverse reactions clinically, such as bleeding and thrombocytopenia, as compared with heparin.

SARS-COV-2 PROTEIN EPITOPES AND USE THEREOF IN PREVENTION AND DIAGNOSIS OF CORONAVIRUS INFECTIONS

Absstract of: WO2025005816A1

The subject of the invention are novel peptides derived from SARS-CoV-2 coronavirus proteins, the peptides being immunoreactive epitopes that interact with convalescent serum, use thereof in prevention and diagnosis of SARS-CoV-2 infections, and an innovative SARS-CoV-2 vaccine, comprising immunoreactive peptides and a thermostable nanoadjuvant that enables effective intranasal administration.

SARS-COV-2 RNA VACCINES AND USES THEREOF

Absstract of: WO2025003929A2

The present disclosure relates to SARS-CoV-2 RNA vaccines and uses thereof. The present disclosure also relates to conventional mRNA vaccines and self-replicating RNA vaccines for the treatment of a SARS-CoV-2 infection or COVID-19.

Methods for the prophylaxis and treatment of COVID and COVID-19

Absstract of: GB2644651A

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and/or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

HIGHLY PURIFIED EICOSAPENTAENOIC ACID, AS FREE FATTY ACID FOR TREATMENT OF CORONAVIRUS-19 (COVID-19)

Absstract of: WO2021191676A1

This present invention relates to the use of eicosapentaenoic acid (EPA) for treating and reducing the negative effects of respiratory virus including coronaviruses and particularly the novel coronavirus-19 (COVID-19). Notably, the eicosapentaenoic acid in the free fatty acid (EPA-FFA) form has a purity of at least has a purity of at least 90%, preferably 95% and more preferably at least 99%. Specifically, the EPA-FFA exhibits a reduction of expressed interleukins, such as IL-6, reduction in D-dimers and a reduction relating to the release of AA.

Application of pyrrolidone benzenesulfonamide compound in preparation of antiviral drugs

Absstract of: CN121943925A

The invention discloses a novel application of a pyrrolone benzenesulfonamide compound, the compound has obvious antiviral activity and low cytotoxicity, can be used as an allosteric inhibitor of coronavirus 3CL protease (3CLpro), and especially shows efficient inhibition capability on SARS-CoV-2 3CLpro. An enzyme activity test and molecular dynamics simulation result shows that the compound is combined with a 3CLpro allosteric site to induce the volume of a catalytic pocket to shrink, so that enzyme activity inhibition is realized, and the drug resistance risk caused by active site mutation is avoided. In-vitro antiviral experiments further show that the compound has a strong inhibition effect on SARS-CoV-2 wild type and various drug-resistant mutant strains (such as E166V and S144M), the EC50 value is as low as the nanomole level, the selection index is high, and the safety is good. Besides, based on the high conservative property of 3CLpro in different coronaviruses, the compound provided by the invention also shows inhibitory activity on other coronaviruses 3CLpro such as SARS-CoV, MERS-CoV and the like, and has broad-spectrum antiviral potential. The compound can be used for preparing medicines for preventing, relieving or treating related diseases caused by coronavirus infection, and has a good clinical application prospect.

Novel coronavirus N protein CD8 + T cell HLA antigen peptide compound and application thereof

Absstract of: CN121949494A

The invention belongs to the technical field of biological pharmacy, and provides a novel coronavirus N protein CD8 + T cell HLA antigen peptide compound and application thereof, and the compound can be applied to preparation of drugs or vaccines for preventing and treating novel coronavirus infection. According to the invention, the effectiveness of the HLA-B * 55: 02-RPQGLPNNTA compound in the invention is verified and evaluated through epitope peptide dominant screening and cell experiments; results show that the HLA-B * 55: 02-RPQGLPNNTA compound can effectively induce CD8 + T cell immune response aiming at the novel coronavirus N protein, and the compound has important guiding significance on development of vaccines/drugs infected by the novel coronavirus.

7-АМINO-1,2,4TRIAZOLO1,5-АPYRIMIDINE DERIVATIVES AND PHARMACEUTICALLY ACCEPTBALE SALTS THEREOF HAVING ANTIVIRAL AND ANTIMICROBIAL ACTIVITY

Absstract of: WO2026089632A1

The invention relates to pharmaceutically active viperin activator compounds having antiviral and antimicrobial activity and the use thereof, as well as to a pharmaceutical composition and a treatment method using said compounds. More particularly, the invention relates to a compound which is a 7-amino-1,2,4triazolo1,5-аpyrimidine derivative, having the general formula (I), where R1 is AlkS, AlkSO, AlkSO2, COOAlk, CON(Alk)2, substituted or unsubstituted Ph, benzyl, furyl, pyridyl; R2 is Н, Alk, Ph; R3 is ОН, OAlk, NHOAlk, NAlk2, or a saturated 6-membered nitrogen-containing heterocyclic ring bound by a nitrogen atom to a carbonyl group and optionally having a second heteroatom in the ring, selected from among X, where X is О, S, NMe; and Alk is Н, Me, Et, Pr or i-Pr, as well as to a pharmaceutically acceptable salt, solvate or hydrate of said compound. The compounds are intended for the treatment and/or prophylaxis of diseases caused by viral and/or microbial infections, such as, for example, diseases caused by influenza, ARI and SARS-CoV-2 viruses, or by ESKAPE group pathogens.

SYSTEMS, DEVICES AND METHODS FOR TREATING POST-INFECTION SYMPTOMS OF COVID-19 USING VESTIBULAR NERVE STIMULATION

Absstract of: US20260115456A1

0000 A method for alleviating post-infection symptoms of COVID-19 in a subject employs vestibular nerve stimulation (VeNS). Upon or after onset of symptoms, an electrode is placed into electrical contact with the subject proximate to a location of the subject's vestibular system. A current source delivers VeNS to the electrode in a sequence of current pulses at a subsensory frequency for a treatment session of approximately 30 minutes to approximately 60 minutes to alleviate post-COVID-19 symptoms including fatigue, malaise, headache, and difficulty concentrating.

THERAPEUTIC DRUG COMBINATIONS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION

Absstract of: US20260115164A1

In alternative embodiments, provided are pharmaceutical compositions comprising combinations of drugs, including products of manufacture and kits, and methods for using them, for treating, preventing, ameliorating, slowing the progress of, decreasing the severity of or preventing a coronavirus infection, or a COVID-19 or a 2019-nCoV (or so-called Wuhan coronavirus) infection, or an infection caused by a virus in the subfamily Orthocoronavirinae, or a virus in the family Coronaviridae, or a virus in the order Nidovirales. In alternative embodiments, combinations, or cocktails, of a drug or drugs as provided herein are administered either enterally, parenterally and/or by inhalation. In alternative embodiments, combinations, or cocktails, of drugs as provided herein are used to block intracellular metabolic pathways and prevent progression of the infection to clinical illness and death. In alternative embodiments, novel aerosol, spray or mist or powder formulations for inhalation are provided.

INHIBITORS OF ACID SPHINGOMYELINASE FOR PREVENTING AND TREATING THE COVID-19 DISEASE

Absstract of: ZA202300974B

The present invention relates to the preventive and therapeutic uses of acid sphingomyelinase inhibitors (FIASMAs) such as psychotropic medications and non-psychotropic compounds having FIASMA activity, for lowering the risk of death and/or intubation in patient suffering from a viral infection caused by at least one betacoronavirus, in particular by the SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2).

SARS-CoV-2 Monoclonal antibodies against SARS-CoV-2 and hybridoma cell line producing the same

Absstract of: KR20260058252A

본 발명은 SARS-CoV-2 바이러스에 대한 단일클론항체 및 이를 생산하는 하이브리도마 세포주에 관한 것이다.

A METHOD OF PROVIDING PEPTIDES

Absstract of: EP4733768A2

0001 A method of identifying stable peptides from a protein, said method comprising: obtaining a peptide from a protein; comparing a solvent-accessible surface area (SASA) of the peptide with a SASA of a corresponding peptide region within the protein; using a result of the comparison to determine whether or not the peptide is structurally stable relative to the corresponding peptide region within the protein. Also disclosed is use of the method to identify stable immunogenic epitopes of SARS-CoV-2, and methods of detecting an antibody response.

METHOD OF DETECTING SARS-COV-2

Absstract of: WO2024263910A1

Provided is method of detecting SARS-CoV-2 in a sample, including amplifying polynucleotides in the sample to form subgenomic amplicons using a forward subgenomic primer and a reverse subgenomic primer, wherein the forward subgenomic primer hybridizes to a forward subgenomic primer target of a subgenomic SARS-CoV-2 N protein transcript or its complement and the reverse subgenomic primer hybridizes to a reverse subgenomic primer target of the subgenomic SARS-CoV-2 transcript or its complement, and detecting an amount of hybridization of a subgenomic SARS-CoV-2 transcript probe to the subgenomic amplicons, wherein the subgenomic SARS-CoV-2 transcript probe hybridizes to a probe target of the subgenomic amplicons, wherein the probe target of the subgenomic amplicons includes at least a portion of a leader sequence, a transcriptional regulatory sequence, and at least a portion of a junction region between the transcriptional regulatory sequence and a coding sequence of the subgenomic SARS-CoV-2 transcript and the probe target is between the forward subgenomic primer target and the reverse subgenomic primer target

Aryl-substituted dihydronaphthalene lignan compound and application thereof

Nº publicación: CN121930089A 28/04/2026

Applicant:

CENTRAL SOUTH UNIV
\u4E2D\u5357\u5927\u5B66

Absstract of: CN121930089A

The invention provides a dextro-aryl substituted dihydronaphthalene lignan compound, the structure of the compound is shown as (I), and the compound plays a role in inhibiting cell lysis death by inhibiting MLKL phosphorylation activation, especially inhibiting COVID-19 symptoms caused by inflammatory factor storm.